Ketorolac Grindeks

Ketorolac Trometamol, the active ingredient in Ketorolac Grindeks, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an injectable solution for intramuscular and intravenous use. It provides short‑term relief of moderate to severe acute pain, including postoperative pain, where opioid use is undesirable.

GNH USA supplies Ketorolac Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, sourced from the EU market and meeting EU quality standards under strict regulatory compliance.

Ketorolac Trometamol is an NSAID used for acute pain management in the postoperative and trauma settings.

- Acute postoperative pain: delivers rapid analgesia to reduce the need for opioid medication. - Moderate to severe acute pain: offers short‑term relief when oral analgesics are insufficient. - Situations where opioid use is undesirable: serves as a non‑opioid alternative for effective pain control.

Ketorolac may cause a range of adverse reactions, from mild to severe. Awareness of common and serious events helps clinicians monitor patients appropriately.

Common Side Effects: - Injection site pain: discomfort at the site of administration. - Nausea: feeling of queasiness often occurring shortly after dosing. - Vomiting: expulsion of stomach contents, sometimes accompanying nausea. - Dizziness: light‑headed sensation that may affect balance. - Headache: mild to moderate cranial pain. - Diarrhea: loose stools occurring after treatment.

Serious or Rare Side Effects: - Gastrointestinal bleeding: potentially life‑threatening hemorrhage in the stomach or intestines. - Renal impairment: reduced kidney function, especially in patients with pre‑existing renal disease. - Severe hypersensitivity reactions: including anaphylaxis, skin rash, or angioedema. - Cardiovascular thrombotic events: increased risk of heart attack or stroke. - Liver dysfunction: elevated liver enzymes indicating hepatic injury. - Hematologic abnormalities: such as thrombocytopenia or leukopenia.

Ketorolac requires careful patient assessment and monitoring to minimize risks.

- Renal function: evaluate kidney status before initiating therapy and avoid prolonged use in renal impairment. - Bleeding risk: contraindicated in patients with active peptic ulcer disease or uncontrolled bleeding. - Pregnancy: category C; use only when potential benefit justifies potential fetal risk. - Concomitant NSAIDs or anticoagulants: increase risk of gastrointestinal bleeding and should be avoided. - Duration of therapy: limit to a maximum of five days to reduce adverse event incidence. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ketorolac can interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin, heparin): additive risk of serious bleeding. - Other NSAIDs or aspirin: heightened gastrointestinal toxicity and ulcer risk.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may diminish renal perfusion, especially in volume‑depleted patients. - Diuretics: combined use can exacerbate renal function decline. - Lithium: NSAIDs can reduce lithium clearance, leading to toxicity.